Origimm develops preventive and therapeutic products that act against those skin-colonizing bacteria that can induce skin disease or internal infections (e.g. infections associated with the insertion of prosthetic implants or medical devices).

Our lead program is the immune therapy against Propionibacterium (Cutibacterium) acnes for treatment of acne vulgaris. Clinical studies are ongoing.

continue reading…